NCT00732420 is a Phase 1 clinical trial of topotecan in Solid Tumours, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00732420?

NCT00732420 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00732420?

Interventions in NCT00732420: topotecan, pazopanib.

What condition does NCT00732420 study?

NCT00732420 studies Solid Tumours.

Is NCT00732420 still recruiting?

NCT00732420 is currently completed. Last updated 13 November 2017.

Last reviewed 2017-11-13 · How we verify

NCT00732420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Completed Phase 1 Last updated 13 November 2017

What this trial tests

Phase 1 trial testing topotecan in Solid Tumours in 68 participants. Completed in 12 June 2013.

Timeline

24 September 2008

Primary endpoint
12 June 2013

12 June 2013

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	screening
Enrollment	68
Start date	24 September 2008
Primary completion	12 June 2013
Estimated completion	12 June 2013
Sites	3 locations across Netherlands, United States

Drugs / interventions tested

topotecan (topotecan) — full drug profile →
pazopanib — full drug profile →

Conditions studied

Solid Tumours — all drugs for Solid Tumours →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determined what dose of topotecan can be safely given with daily pazopanib.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Kerklaan BM, Lolkema MP, Devriese LA, Voest EE, et al · · 2015 · cited 16× · PMID 26291057 · DOI 10.1038/bjc.2015.257

Verify or expand the search:

Other trials of topotecan

Trials testing the same drug.

NCT04697628 — Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer · Phase 3 · completed
NCT01931098 — Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without P · Phase 2 · completed
NCT02500459 — Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection · EARLY_PHASE1 · terminated
NCT01857934 — Therapy for Children With Advanced Stage Neuroblastoma · Phase 2 · completed
NCT00976911 — AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer · Phase 3 · completed

Other recruiting trials for Solid Tumours

Currently open trials in the same condition.

NCT07391670 — A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval · Phase 1 · recruiting
NCT07446855 — Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homo · Phase 1, PHASE2 · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07165067 — A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00732420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 13 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00732420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing